Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 399-405

  La Piana, Giuseppe Emanuele ^a   Corda, Luciano ^b   Bertella, Enrica ^a   Montemurro, Luigi Taranto ^a   Pini, Laura ^a   Tantucci, Claudio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Formoterol; Long acting 2 agonists; Salbutamol

Indexed keywords

FORMOTEROL; SALBUTAMOL; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTICLE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; POWDER INHALER; TREATMENT DURATION; AGED; BIOAVAILABILITY; CLINICAL TRIAL; DRUG MONITORING; INHALATIONAL DRUG ADMINISTRATION; LUNG VENTILATION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; TREATMENT OUTCOME;

EID: 84856014346     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S22179     Document Type: Article

References (21)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Respir Crit Care Med. 2007;176: 532-555.
2. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2008;42:1832-1842.
3. Chapman KR, Bowie OM, Goldstein RS, et al. Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group. Can Med Assoc J. 1992; 147:420-428.
4. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;19:CD001104.
5. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J P, Milic-Emili J. Effect of salbutamol on dynamic hyperinfation in chronic obstructive pulmonary disease patients. Eur Respir J. 1998;12:799-804.
6. Postma DS, de Vries K, Koeter GH, Sluiter HJ. Independent infuence of reversibility of airflow obstruction and nonspecifc hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis. 1986;134:276-280.
7. Cazzola M, Di Perna F, Noschese P, et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J. 1998;11:1337-1341.
8. Manning HL. Bronchodilator therapy in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2000;6:99-103.
9. American Thoracic Society. European Respiratory Society Task Force. Standardization of lung function testing. Eur Respir J. 2005;26: 319-338.
10. American Thoracic Society. European Respiratory Society Task Force. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26:948-968.
11. Koulouris NG, Valta P, Lavoie A, et al. A simple method to detect expiratory flow limitation during spontaneous breathing. J Eur Respir J. 1995;8:306-313.
12. Tantucci C, Pinelli V, Cossi S, et al. Reference values and repeatability of inspiratory capacity for men and women aged 65-85. Respir Med. 2006;100:871-877.
13. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function test. European community for steel and coal. Offcial statement of the european society. Eur Respir J Suppl. 1993;16:5-40.
14. Cazzola M, MacNee W, Martinez FJ, et al. ATS/ERS Task Force. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-468.
15. Gross NJ, Kerwin E, Levine B, et al. Nebulized formoterol fumarate: dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008; 21:818-823.
16. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:205-215.
17. Cohen J, Postma DS, Vink-Klooster K, et al. FVC to slow inspiratory vital capacity ratio: a potential marker for small airways obstruction. Chest. 2007;132:1198-1203.
18. Hirst PH, Bacon RE, Pitcaim GR, Silvasti M, Newman S P. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95:720-727.
19. Spina D, Rigby RJ, Paterson J W, Goldle RG. Autoradiographic localization of β-adrenoceptors in asthmatic human lung. Am Rev Respir Dis. 1989;140:1410-1415.
20. Hoffman EA, Chiplunkar R, Casale TB. CT scanning confrms beta receptor distribution is greater for small versus large airways. Am J Respir Crit Care Med. 1997;155:Abstr 855.
21. Tweeddale PM, Alexander F, McHardy GJ. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987;42:487-490.